EP2077832A1 - Verwendung von verbindungen der avermectin-familie zur behandlung von hauterkrankungen bei menschen - Google Patents

Verwendung von verbindungen der avermectin-familie zur behandlung von hauterkrankungen bei menschen

Info

Publication number
EP2077832A1
EP2077832A1 EP07823874A EP07823874A EP2077832A1 EP 2077832 A1 EP2077832 A1 EP 2077832A1 EP 07823874 A EP07823874 A EP 07823874A EP 07823874 A EP07823874 A EP 07823874A EP 2077832 A1 EP2077832 A1 EP 2077832A1
Authority
EP
European Patent Office
Prior art keywords
use according
compounds
composition
formula
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07823874A
Other languages
English (en)
French (fr)
Inventor
Alexandre Kaoukhov
Cécile COUSIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Publication of EP2077832A1 publication Critical patent/EP2077832A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Definitions

  • the present invention relates to the use of at least one compound of formula (I) or its derivatives, preferably latidectin, for the manufacture of a pharmaceutical composition intended for the treatment of dermatological conditions in humans, in particular rosacea.
  • Rosacea is a chronic and progressive joint inflammatory dermatosis related to vascular relaxation. It mainly affects the central part of the face and is characterized by facial redness or hot flushes, facial erythema, papules, pustules, and telangiectasias. In severe cases, particularly in man, a facial elephantiasis may develop which most commonly presents as swelling of the soft tissue of the nose producing bulbous swelling called rhinophyma.
  • Rosacea usually occurs between the ages of 25 and 70, and is much more common in fair-skinned people. It affects more particularly women, although this affection is generally more severe in the man. Rosacea is chronic and persists for years with periods of exacerbation and remission.
  • rosacea The pathogenesis of rosacea is poorly understood. Many factors can be involved without necessarily inducing this condition. These are for example psychological factors, gastrointestinal disorders, environmental factors (exposure to the sun, temperature, humidity) and emotional (stress), food (alcohol, spices), hormonal, vascular, or even an infection with Helicobacter pillori.
  • rosacea can be treated by topical treatments, for example metronidazole, azelaic acid, benzoyl peroxide, or retinoic acid.
  • topical treatments for example metronidazole, azelaic acid, benzoyl peroxide, or retinoic acid.
  • R represents an alkyl radical having from 1 to 6 carbon atoms
  • R represents an alkyl radical having from 1 to 6 carbon atoms
  • Alkyl having 1 to 6 carbon atoms means a linear or branched alkyl radical, and preferably methyl, ethyl, propyl, isopropyl, butyl and hexyl radicals.
  • derivatives of compounds of formula (I) is meant in particular pharmaceutically acceptable salts, and in particular salts formed with a pharmaceutically acceptable acid or base.
  • the acids may be selected from benzoic acid, optionally substituted, benzenesulfonic acid, citric acid, maleic acid, tartaric acid, phosphoric acid, salicylic acid and gallic acid.
  • the bases may be chosen from alkali metal and alkaline earth metal salts, such as lithium, calcium, sodium potassium or magnesium salts, or salts of aminated heterocycles such as piperidine or morpholine salts.
  • the compounds of formula (I) are those for which: a. R is a methyl radical.
  • R is a methyl radical.
  • Such a compound corresponds to compound A3 (or 1- [4- [(methoxyacetyl) amino] phenyl] cyclopentanecarboxylate.
  • the compounds A3 and A4 are used in a mixture, said mixture being called latidectin.
  • Latidectin belongs to the group of avermectins, a family of closely related compounds produced by the fungus Streptomyces avermitilis, which share a common broad-spectrum toxicity for nematodes, arthropods and several other pests.
  • compositions for human use comprise, in a pharmaceutically acceptable medium, at least one compound of formula (I) or its derivatives, preferably a mixture of these compounds, preferably latidectin.
  • pharmaceutically acceptable medium is meant a medium compatible with the skin, mucous membranes and / or integuments.
  • the pharmaceutical composition that can be used according to the invention is intended for the treatment of the skin and can be administered topically, parenterally or orally. Preferably, the composition is administered topically.
  • the pharmaceutical composition may be in liquid, pasty or solid form, in the form of powders and more particularly in the form of tablets, capsules, dragees, syrups, suspensions, solutions, powders, granules , emulsions, microspheres or nanospheres or lipid or polymeric vesicles allowing controlled release.
  • composition may be in the form of solutions or suspensions for infusion or injection.
  • the composition may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks, ointments, powders, soaked swabs, syndets, wipes, solutions, gels, sprays, mousses, suspensions, lotions, sticks, shampoos, or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or lipid or polymeric vesicles or polymeric patches and hydrogels allowing controlled release.
  • This composition for topical application may be in anhydrous form, in aqueous form or in the form of an emulsion.
  • the topical pharmaceutical composition according to the invention is in the form of a cream or lotion emulsion, a gel, or a solution.
  • the composition according to the invention when in the form of an emulsion, it comprises at least one surfactant.
  • the conventional emulsions as described in the prior art are unstable quasi-homogeneous systems of two immiscible liquids, one of which is dispersed in the other in the form of fine droplets (micelles).
  • This dispersion is stabilized thanks to the action of surfactant emulsifiers which modify the structure and the ratio of the forces at the interface, and thus increase the stability of the dispersion by reducing the interfacial tension energy.
  • the surfactant emulsifiers are amphiphilic compounds which have a hydrophobic part having an affinity for the oil and a hydrophilic part having an affinity for water thus creating a link between the two phases. Ionic or nonionic emulsifiers thus stabilize the oil / water emulsions by adsorbing at the interface and forming lamellar layers of liquid crystals.
  • the emulsifying power of nonionic surfactants is closely related to the polarity of the molecule. This polarity is defined by the HLB (Hydrophile / Lipophilic Balance).
  • HLB Hydrophilic Balance
  • the conventional emulsions are generally stabilized by a mixture of surfactants whose HLB may be quite different but whose proportion in the mixture corresponds to the required HLB of the fatty phase to be emulsified.
  • surfactants that may be used according to the invention, mention may be made, by way of example, of the glyceryl / PEG100 stearate sold under the name Arlacel 165FL by the company Uniqema or under the name Simulsol 165 by the company SEPPIC, esters of polyoxyethylenated fatty acids such as Arlatone 983 from the company Uniqema or the polyoxyethylenated stearyl alcohol (2) sold under the name Brij72 combined with the polyethylenated stearyl alcohol (21) sold under the name Brij721 by the company Uniqema, sorbitan esters such as sorbitan oleate sold under the name Arlacel 80 by ICI or sold under the name of Crill 4 by Croda, sorbitan sesquioleate sold under the name Arlacel 83 by the company ICI or sold under the name of Montane 83 by the company SEPPIC, or the isostearate of sorbitan;
  • composition according to the invention advantageously comprises up to 15% by weight suitable surfactant emulsifier, preferably from 2 to 12% by weight and more particularly from 2 to 6% by weight relative to the total weight of the composition.
  • composition in the form of an emulsion thus comprises: a) an oily phase comprising fatty substances; b) at least one surfactant emulsifier; c) at least one compound selected from the compounds of formula (I) and their derivatives; d) one or more solvents and / or propenetrants of the active substance (s); e) and water.
  • the oily phase of the composition according to the invention may comprise, for example, vegetable, mineral, animal or synthetic oils, silicone oils, Guerbet alcohols or other fatty substances and mixtures thereof.
  • paraffin oils of different viscosity such as Primol 352, Marcol 82, Marcol 152 sold by Esso.
  • sweet almond oil there may be mentioned sweet almond oil, palm oil, soybean oil, sesame oil, sunflower oil.
  • animal oil there may be mentioned lanolin, squalene, fish oil, mink oil.
  • Synthetic oils that may be mentioned include esters, such as cetearyl isononanoate sold under the name Cetiol SN by the company Cognis France, diisopropyl adipate, for example, the product sold under the name Ceraphyl 230 by the company ISF, palmitate isopropyl as the product sold under the name Crodamol IPP by the company Croda, caprylic capric triglyceride such as Miglyol 812 sold by the company HuIs / Lambert River.
  • esters such as cetearyl isononanoate sold under the name Cetiol SN by the company Cognis France
  • diisopropyl adipate for example, the product sold under the name Ceraphyl 230 by the company ISF, palmitate isopropyl as the product sold under the name Crodamol IPP by the company Croda
  • caprylic capric triglyceride such as Miglyol 812 sold by the company HuIs
  • silicone oil mention may be made of a dimethicone such as the product sold under the name of Dow Corning 200 fluid, a cyclomethicone such as the product sold under the name Dow Corning 244 fluid by Dow Corning or the product sold under the name Mirasil CM5 by SACI-CFPA.
  • fatty acids such as stearic acid, fatty alcohols such as stearyl alcohol, cetostearyl alcohol and cetyl alcohol or their derivatives, and waxes such as beeswax or wax. carnauba, candellilla wax, as well as gums, in particular silicone gums.
  • ingredients of the oily phase may be chosen in a varied manner by those skilled in the art in order to prepare a composition having the desired properties, for example in consistency or in texture.
  • the oily phase of the composition according to the invention comprises a synthetic oil and / or a silicone oil, as synthetic oil, isopropyl palmitate is preferred as the product sold under the name Crodamol IPP by the company Croda or isopropyl myristate, such as the product sold under the name Crodamol IPM by Croda, as silicone oil, dimethicone is preferred.
  • the oily phase of the emulsion according to the invention may be present in a content of between 3 and 50% by weight relative to the total weight of the composition and preferably between 6 and 20% by weight.
  • composition according to the invention comprises from 0.001 to 10% of compound (s) of formula (I) or its derivatives by weight relative to the total weight of the composition.
  • composition according to the invention contains from 0.1 to 5% of compound (s) of formula (I) or its derivatives by weight relative to the total weight of the composition.
  • solvents and / or propenetrating compounds of formula (I) or their derivatives mention will preferably be made of propylene glycol, alcohols of the ethanol, isopropanol, butanol, N-methyl 2 pyrrolidone or DMSO type. polysorbate 80, phenoxyethanol and mixtures thereof.
  • the composition of the invention contains from 0.1% to 20% and preferably from 1% to 10% of a solvent and / or propenetrating compounds of formula (I) or their derivatives.
  • the composition of the invention also contains water ranging from 30 to 95% and preferably from 60 to 80% by weight relative to the total weight of the composition.
  • the water used in the composition according to the invention will preferably be purified water.
  • the composition according to the invention may also be in the form of a gel; it then comprises one or more gelling compounds, ranging from 0.01 to 5% by weight relative to the total weight of the composition.
  • gelling agents that can be used in the composition according to the invention, mention may be made of carboxyvinyl polymers (carbomers) and, by way of non-limiting examples of carbomer, Carbopol 981, Carbopol ETD 2020, Carbopol 980, Carbopol Ultrez 10 NF, Pemulen TR1 sold by the company NOVEON.
  • cellulose derivatives for example hydroxypropylmethylcellulose, or hydroxyethylcellulose
  • xanthan gums aluminum / magnesium silicates such as Veegum K or Veegum Ultra sold by Vanderbilt, guar gums and the like
  • polyacrylamides such as the polyacrylamide / isoparaffin C13-14 / laureth-7 mixture such as for example sold by SEPPIC under the name Sepigel 305 or the acrylamide mixture, AMPS copolymer dispersion 40% / isohexadecane under the name of Simulgel 600PHA, or the family of modified starches such as Solanace Structure sold by National Starch or their mixtures.
  • composition of the invention preferably contains from 0.01% to 5%, and preferably from 0.1 to 3% of gelling agent.
  • composition when in the form of a solution, it comprises, in addition to the compounds of formula (I) or their derivatives, an aqueous or oily solution, and optionally one or more solvents and / or propenetrating actives as described above.
  • composition according to the invention may also contain inert additives or combinations of these additives, such as
  • UV-A and UV-B filters are UV-A and UV-B filters
  • additives may be present in the composition of 0.001 to 20% by weight relative to the total weight of the composition.
  • the invention also relates to the use of the composition according to the invention for the manufacture of a pharmaceutical preparation for treating dermatological conditions.
  • the use of the compounds of formula (I) or their derivatives as a medicament, and more particularly for the manufacture of a topical pharmaceutical composition for human use according to the invention is particularly intended for the treatment of rosacea, acne vulgaris, seborrheic dermatitis, perioral dermatitis, acneiform eruptions, transient acantholytic dermatitis, and acne miliaris necrotica.
  • compositions comprising compounds of formula (I) or their derivatives will now be given.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
EP07823874A 2006-09-28 2007-09-27 Verwendung von verbindungen der avermectin-familie zur behandlung von hauterkrankungen bei menschen Withdrawn EP2077832A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653996A FR2906465B1 (fr) 2006-09-28 2006-09-28 Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques chez l'homme
PCT/FR2007/052039 WO2008037934A1 (fr) 2006-09-28 2007-09-27 Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques chez l'homme

Publications (1)

Publication Number Publication Date
EP2077832A1 true EP2077832A1 (de) 2009-07-15

Family

ID=37813802

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07823874A Withdrawn EP2077832A1 (de) 2006-09-28 2007-09-27 Verwendung von verbindungen der avermectin-familie zur behandlung von hauterkrankungen bei menschen

Country Status (4)

Country Link
US (1) US20120010277A1 (de)
EP (1) EP2077832A1 (de)
FR (1) FR2906465B1 (de)
WO (1) WO2008037934A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2274617A4 (de) 2008-04-10 2011-11-09 Massachusetts Inst Technology Verfahren zur erkennung und verwendung von auf krebsstammzellen abzielenden mitteln

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192319A1 (en) * 1996-09-19 2005-09-01 Albert Boeckh Spot-on formulations for combating parasites
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
JP2003064082A (ja) * 2001-08-29 2003-03-05 Sankyo Co Ltd アベルメクチン誘導体
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008037934A1 *

Also Published As

Publication number Publication date
WO2008037934A1 (fr) 2008-04-03
FR2906465B1 (fr) 2008-11-28
FR2906465A1 (fr) 2008-04-04
US20120010277A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
EP2374449B1 (de) Zusammensetzung, die aus mindestens einer wässrigen Phase und mindestens einer Ivermectin enthaltenden Fettphase besteht
JP2006524212A (ja) 皮膚科学的疾患の治療のためのアイバメクチンの使用
CA2745457A1 (fr) Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
FR2867684A1 (fr) Gel creme contenant de l'ivermectine
FR2924944A1 (fr) Composition a base d'une avermectine et du soufre ou d'un derive du soufre, notamment pour le traitement de la rosacee
EP2077848A1 (de) Verwendung von verbindungen der avermectin-familie zur behandlung von hauterkrankungen
EP2124932A2 (de) Verwendung von verbindungen der milbemycin-familie zur behandlung von hauterkrankungen bei menschen
EP2077849A1 (de) Verwendung von verbindungen der avermectin-familie zur behandlung von hauterkrankungen bei menschen
EP2077833A1 (de) Verwendung von verbindungen der milbemycin-familie zur behandlung von hauterkrankungen bei menschen
CA2672377A1 (fr) Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques liees a un desordre de la keratinisation pouvant avoir une composante immuno-allergique inflammatoire
EP2077831B1 (de) Verwendung von 6'-ethyl-lepimectin, 6'-methyl-lepimectin oder derivaten davon zur behandlung von hauterkrankungen bei menschen
US20090281175A1 (en) Avermectin compounds and treatment of dermatological disorders in humans therewith
EP2077832A1 (de) Verwendung von verbindungen der avermectin-familie zur behandlung von hauterkrankungen bei menschen
EP2506851A1 (de) Verwendung einer dipyridylverbindung zur behandliung von rosazea

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090428

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20121217